Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs
- PMID: 1662289
- DOI: 10.1016/0022-2836(91)90585-t
Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs
Abstract
The distributions of DNA cleavage sites induced by topoisomerase II in the presence or absence of specific drugs were mapped in the simian virus 40 genome. The drugs studied were 5-iminodaunorubicin, amsacrine (m-AMSA), teniposide (VM-26) and 2-methyl-9-hydroxyellipticinium; each produced a distinctive pattern of enhanced cleavage. Consistently intense cleavage, both in the presence and in the absence of drugs, occurred in the nuclear matrix-associated region. Since topoisomerase II is a major constituent of the nuclear matrix, and cleavage complexes include a covalent link between topoisomerase II and DNA, the findings suggest that topoisomerase II may function to attach DNA to the nuclear matrix. Cleavage usually occurred on both DNA strands with the expected four base-pair 5' stagger, and strong sites tended to occur within A/T runs such as have been associated with binding to the nuclear scaffold. Intense cleavage was present also in the replication termination region, but was absent from the vicinity of the replication origin. Cleavage intensities were found to change with time in a manner that depended both on the site and on the drug, suggesting that topoisomerase II can move along the DNA from a kinetically preferred site to a thermodynamically preferred site.
Similar articles
-
Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.Nucleic Acids Res. 1991 Nov 11;19(21):5973-80. doi: 10.1093/nar/19.21.5973. Nucleic Acids Res. 1991. PMID: 1658748 Free PMC article.
-
Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers.Biochemistry. 1993 Jan 12;32(1):145-52. doi: 10.1021/bi00052a020. Biochemistry. 1993. PMID: 8380330
-
Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.Cancer Res. 1992 Jun 1;52(11):3125-30. Cancer Res. 1992. PMID: 1317259
-
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.Semin Cancer Biol. 1991 Aug;2(4):235-44. Semin Cancer Biol. 1991. PMID: 1655118 Review.
-
Chromosomal DNA loops may constitute basic units of the eukaryotic genome organization and evolution.Crit Rev Eukaryot Gene Expr. 1999;9(3-4):279-83. doi: 10.1615/critreveukargeneexpr.v9.i3-4.120. Crit Rev Eukaryot Gene Expr. 1999. PMID: 10651244 Review.
Cited by
-
Hyperthermia, thermotolerance and topoisomerase II inhibitors.Br J Cancer. 1995 Aug;72(2):333-8. doi: 10.1038/bjc.1995.334. Br J Cancer. 1995. PMID: 7640214 Free PMC article.
-
Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.PLoS One. 2014 Dec 9;9(12):e114904. doi: 10.1371/journal.pone.0114904. eCollection 2014. PLoS One. 2014. PMID: 25489853 Free PMC article.
-
Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9802-7. doi: 10.1073/pnas.171309898. Epub 2001 Aug 7. Proc Natl Acad Sci U S A. 2001. PMID: 11493704 Free PMC article.
-
Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: implications for interactions with intercalating anticancer agents.Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12498-503. doi: 10.1073/pnas.2032456100. Epub 2003 Oct 1. Proc Natl Acad Sci U S A. 2003. PMID: 14523238 Free PMC article.
-
DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.Cancer Chemother Pharmacol. 1993;32(2):103-8. doi: 10.1007/BF00685611. Cancer Chemother Pharmacol. 1993. PMID: 8387398 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources